Background：Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate ADC targeted to tissue factor TF, a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E MMAE via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl mc-val-cit-PABC type linker. Based on its high expression on many solid tumors including ovarian, prostate, bladder, esophageal, endometrial and lung and its rapid internalization, TF is considered a suitable target for antibody-drug conjugates. In pre-clinical trials tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth. Genmab and Seattle Genetics are jointly developing tisotumab vedotin. In a Phase IIa study, preliminary data demonstrated a manageable safety profile and encouraging efficacy ORR 37% in relapsed, recurrent or metastatic cervical cancer.
Alternative Names：HuMax-TF-ADC, TF-011-MMAE, HuMax-TF,
